Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib | SpringerLink
Cancers | Free Full-Text | Progression-Free and Overall Survival of First- Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC - ScienceDirect
Dosing schedules and outcomes in patients with first-line sunitinib for advanced renal cell carcinoma
5-year Follow-Up: First-Line Nivolumab Plus Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma - Cancer Therapy Advisor
Frontiers | Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
Sunitinib - Wikipedia
Overall survival rates of advanced gastrointestinal stromal tumor... | Download Scientific Diagram
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers | BMC Cancer | Full Text
Overall survival for first-line IO combination therapies. CI =... | Download Scientific Diagram
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma | Future Oncology
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial - The Lancet
Frontiers | Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response ...
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review - ScienceDirect
IJMS | Free Full-Text | A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy
Cancers | Free Full-Text | Progression-Free and Overall Survival of First- Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma | Future Oncology
Overall survival with sorafenib and sunitinib compared with other... | Download Scientific Diagram
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Sunitinib effectiveness and safety as first line treatment in metastatic renal cell carcinoma, in the Costa Rican population
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Ginsenoside Rh2 sensitizes the anti-cancer effects of sunitinib by inducing cell cycle arrest in renal cell carcinoma | Scientific Reports
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
